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Aims. To evaluate the feasibility and eﬃcacy of a gestational diabetes (GDM) recall register on the long-term screening uptake
postpartum and to evaluate the prevalence of prediabetes postpartum. Methods. Evaluation of a GDM recall register
implemented in 66 obstetrical centers in the northern part of Belgium from 2009 to 2016. Registrants receive yearly reminders
to have a fasting plasma glucose test in primary care to timely detect prediabetes. Results. After 6 years, 7269 women were
registered. The yearly response rates varied from 74.4% after the ﬁrst year to 61.8% after the ﬁfth year. The number of women
who reported a screening test varied from 67.4% after the ﬁrst year to 71.9% after the ﬁfth year. Compared to women who
responded at least once to a reminder, women who never responded were more often <30 years (41.4% versus 33.9%, p < 0 001)
and were more often obese (29.3% versus 20.8%, p ≤ 0 001). Over a period of 6 years, 7.3% (CI 6.0%–8.8%) developed diabetes
and 27.4% (CI 23.9%–31.0%) developed impaired fasting glycaemia. Conclusion. We show now the long-term feasibility and
eﬃcacy of a GDM recall register to stimulate screening postpartum. One-third of women developed prediabetes within 6 years.
1. Introduction
Gestational diabetes (GDM) has been deﬁned as “any degree
of glucose intolerance with onset or ﬁrst recognition during
pregnancy,” but many associations recommend now to
screen for unknown diabetes at ﬁrst prenatal visit (espe-
cially in women at risk) before a diagnosis of GDM can
be made [1, 2]. The incidence of GDM is rising globally, and
it represents an important modiﬁable risk factor for adverse
pregnancy outcomes such as macrosomia and preeclampsia
[3, 4]. Since 2013, theWHOrecommends theuse of the “Inter-
national Association of Diabetes and Pregnancy Study
Groups” (IADPSG) criteria for GDM [5]. Using the 2013
WHO criteria, GDM prevalence increases signiﬁcantly in
most populations and aﬀects 9–35% of pregnancies [6, 7].
Shortly after the delivery, glucose values generally nor-
malize again, but on the long term, women with a history
of GDM have a risk that is 7 times higher compared to
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women without a history of GDM to develop type 2 diabetes
[8]. Women with a history of GDM are also at increased risk
to develop the metabolic syndrome [9]. Timely detection of
glucose intolerance postpartum is important since progres-
sion to type 2 diabetes can be prevented with 50% by lifestyle
intervention and/or metformin therapy [10, 11]. The
American Diabetes Association (ADA) advises therefore to
screen women with a history of GDM between 6 and 12
weeks after the delivery using the 2-hour 75 g OGTT [1].
The ADA further advises that these women should have life-
long screening for the development of glucose intolerance, at
least every 3 years [1]. Due to the increasing prevalence of
GDM, a growing number of women will need long-term
follow-up postpartum to timely detect and treat glucose
intolerance. This is challenging due to the often low atten-
dance rates at screening tests postpartum and the need for
long-term follow-up programs in primary care [12–14].
Many studies have reported low postpartum testing rates in
routine clinical practice with only 30–50% of women with
recent GDM receiving a fasting plasma glucose (FPG) or
OGTT within one year after the delivery, and follow-up rates
after one year are often even lower [15–19]. Small studies
have shown that the use of reminders send to patients and/
or health care professionals can increase the postpartum
screening uptake [20]. However, very few studies have evalu-
ated the eﬃcacy of reminders after the ﬁrst year postpartum
[20, 21]. Large population-based reports are therefore needed
that evaluate long-term postpartum screening programs for
women with a history of GDM. Since 2009, the GDM recall
register, the “Sweet Pregnancy” project, has been established
in the northern part of Belgium (Flanders) [22]. This is cur-
rently the only system of long-term follow-up of women with
GDM in Belgium. Women registered in the project receive
annual reminders to have a FPG screening test in primary
care to timely detect glucose intolerance. We evaluated the
feasibility and eﬃcacy of the GDM recall register on the
long-term screening uptake postpartum in Flanders. Addi-
tionally, we also report on the prevalence of diabetes and
impaired fasting glycaemia (IFG) in women registered in
the recall system over a period of max. 6 years, from October
2009 until October 2016.
2. Methods
In October 2009, the Diabetes Liga launched the GDM recall
register, the “Sweet Pregnancy” project [22]. The Diabetes
Liga is an independent Flemish association representing the
interests of diabetes patients and diabetes-related health care
professionals. The “Sweet Pregnancy” project is an auto-
mated recall register for women with a history of GDM and
is implemented in Flanders. The objective of the register is
to increase the awareness among women with GDM and
health care professionals on the long-term risks associated
with GDM and to stimulate screening postpartum. When
organizing the recall register, it was considered that the rec-
ommendation to have a yearly FPG control by the general
practitioner was more practical and achievable than recom-
mending an OGTT. An OGTT after one year postpartum
was therefore not actively promoted by the project. This
ongoing project is ﬁnanced by the Flemish Government
and is coordinated by the Diabetes Liga with the support of
the Flemish association of family doctors and the Flemish
association of obstetricians and gynecologists.
2.1. Participants. Since October 2009, the “Sweet Pregnancy”
project was introduced to all 66 obstetrical centers in
Flanders. Belgium has a population of 11 million of which
12% are from an ethnic minority background. Of all Belgians,
6.4 million live in Flanders [23]. The background prevalence
of type 2 diabetes in Belgium is 6.5% [24]. The number of
deliveries in Flanders decreases progressively over time with
63877 deliveries in 2015. The mean age at delivery in Flan-
ders is 28.8 years, and 22.7% of pregnant women are over-
weight and 11.4% are obese [25].
There are currently no data on the general prevalence of
GDM in Flanders. A survey performed in 2013 has shown
that screening practices for GDM vary largely between cen-
ters [25, 26]. The most commonly used screening strategy
for GDM in Flanders is still a two-step approach with a
50 g glucose challenge test and 100 g OGTT with the Carpen-
ter and Coustan criteria for GDM, used by 56% of centers,
followed by the one-step screening strategy with the 75 g
OGTT using the 2013 WHO criteria for GDM, implemented
by 25% of centers [26].
2.2. Registration. Figure 1 gives an overview of the recruit-
ment and follow-up on the GDM recall register. Women with
GDM are invited to voluntarily enroll on the register shortly
after the diagnosis. During the recruitment, women are given
an information sheet, the registration form, and a prepaid
envelope. The completed registration form needs to be sent
to the project coordinator of the Diabetes Liga. Since 2013,
women can also register online. The registration form
includes an informed consent to register participants’ details
and requests personal contact information, contact details of
their family doctor and obstetrician, woman’s date of birth,
self-reported pregestational weight and length, who diag-
nosed GDM, and by whom and when the registration was
proposed. Consent is also given on this form for the partic-
ipant’s general practitioner and obstetrician to be informed
of their enrolment on the register. The general practitioner
is asked to provide active support for the project by com-
pleting a feedback sheet. Since April 2016, the diabetes team
also receives conﬁrmation of the registration of women in
the project.
2.3. Follow-Up. The ﬁrst recall function involves sending a
letter and email three months after the delivery to the regis-
trants (Figure 1). This letter provides information on the
importance of the prevention and early detection of diabetes.
In addition, registrants are asked to complete a feedback
sheet to check their contact details and to evaluate whether
they received a screening test for diabetes 6–12 weeks post-
partum. When the registrant indicates that a diagnosis of
diabetes was made, a letter is sent to indicate that she will
no longer receive annual reminders to perform a screening
test for diabetes.
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If no diabetes was diagnosed, subsequent reminder letters
and emails are sent to the registrants after 11 months and
yearly thereafter with the advice to visit the general practi-
tioner to check the FPG. The registrant is asked to send the
result of the FPG from each visit at the general practitioner
to the coordinator of the register. If no response was obtained
from the registrant after two months, an extra reminder is
sent by email and/or telephone to try to get a response. Due
to the large number of women registered in the project, since
April 2016, telephone calls for nonresponders have been
replaced by an automated SMS reminder except for the ﬁrst
and ﬁfth years after the registration where a telephone call
is still used. Nonresponders are deﬁned as registrants who
have never returned a response sheet to the coordinator of
the register. To better promote a healthy lifestyle, since Janu-
ary 2016, registrants also receive 8 newsletters during the ﬁrst
two years of the registration with lifestyle tips for the preven-
tion of type 2 diabetes.
The follow-up is stopped when the registrant cannot be
contacted anymore, when the registrant has asked to stop
the follow-up, or when the registrant has indicated that dia-
betes has been diagnosed. All data provided by the registrants
are stored in a secure database managed by the coordinator of
the project.
2.4. Categorization of Postpartum Glucose Testing Results.
Using the ADA criteria, we deﬁned women with a
FPG< 100mg/dl as normal, 100–125mg/dl as IFG, and
≥126mg/dl as having diabetes [1].
2.5. Feedback and Benchmarking. To evaluate the evolution
of registrations and to provide feedback to the centers, an
overview of the number of registrations per center is pro-
vided anonymously every 6 months to each center. The
recruitment per center can thus be compared to other cen-
ters, and this provides valuable benchmarking. As part of
Women are registered at
GDM diagnosis by the
diabetes or obstetrical team 
Conrmation letter of the registration is sent
to the participant, family doctor, obstetrician,
and diabetes team 
First reminder letter and email are sent 3 months aer the
delivery to he participant
Participant returns feedback sheet with information on the screening
test performed 6-12 weeks aer the delivery
Data from the feedback sheet from the participant are
entered into a secure database
Reminder letter and email are sent 11 months aer the delivery and
thereaer aer every year to the participant 
Participant returns feedback sheet with information
on the FPG performed 
Figure 1: Overview of the recruitment and follow-up on the GDM recall register. GDM: gestational diabetes; FPG: fasting plasma glucose.
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quality control, in 2014, an online survey was sent to 500 ran-
domly selected participants (100 women for each year of fol-
low-up) to evaluate the perceived usefulness of the reminders
to stimulate screening postpartum.
2.6. Statistical Analyses. The eﬀectiveness of the GDM recall
register was evaluated by analyzing the recruitment to the
register, the proportion of women returning the feedback
sheet (the number of responders), and the proportion of
women reporting a screening test. Survival analysis tech-
niques for time-to-event outcomes were used to analyze dia-
betes and prediabetes. Outcomes were deﬁned as the time
between delivery and the ﬁrst assessment of prediabetes.
The cumulative risk of diabetes was estimated using the
Kaplan-Meier method, whereas for prediabetes estimation
was based on the cumulative incidence function. Diabetes
without earlier prediabetes was then considered as a compet-
ing risk. Patients without prediabetes were censored at the
last follow-up. The independent contribution of participant
characteristics was analyzed using Cox proportional hazard
models, competing risks being censored. The results are pre-
sented as hazard ratios (HR) with 95% conﬁdence intervals.
The chi-square test was used to test the association between
responder/nonresponder and participant characteristics. A
p value of <0.05 (two tailed) was considered signiﬁcant unless
stated otherwise. Analyses were performed using SAS soft-
ware (version 9.4).
3. Results
3.1. The Number of Registrations over Time and per Center.
Since the start of the register in October 2009, 7269 women
have registered. Yearly, more than 1000 women have regis-
tered in the register (Figure 2). Participation in the register
was generally similar across all provinces, with the highest
rates of registration in West Flanders and Limburg with,
respectively, 138 and 136 registrants per 100,000 inhabitants,
followed by Flemish Brabant and Antwerp with, respectively,
116 and 105 registrations per 100,000 inhabitants. The lowest
number of registration was seen in the province of East
Flanders with 71 registrations per 100,000 inhabitants. Of
all 66 centers, 35% (23) had more than 100 registrations.
Data on length and weight of the registrants were reported
in the feedback sheet by 97.2% of all registrants, and 94.3%
of all registrants provided contact details. The mean age of
the registrants was 32±4.8 years, 27.9% were overweight,
and 23.2% were obese. Of all obstetricians in Flanders, 76%
(511) came in contact with the project. Of all general practi-
tioners in Flanders, 39.3% (3323) came in contact with the
project and 69.4% (2307) of them indicated their active sup-
port for the project.
3.2. The Number of Responses and Screening Tests over Time.
Of all registrants, 84.4% (5465) responded to the letter sent
three months after the delivery and 58.8% (3215) of
responders indicated that they had received a screening test
to detect glucose intolerance in early postpartum and 2.8%
(91) reported to have diabetes based on the early postpartum
screening test. Table 1 gives an overview of the number of
responses and the number of responders who received a
screening test by each year of follow-up. The yearly response
rates varied from 74.4% after the ﬁrst year to 61.8% after the
ﬁfth year. The primary response rate before an extra
reminder was sent was 23.3% after the ﬁrst year and 22.0%
after the ﬁfth year. Of all responders, 67.4% reported a
screening test after the ﬁrst year and 71.9% after the ﬁfth
year. Table 2 gives an overview of the number of responses
and screening tests of all registrants who delivered before
October 2011 and received a yearly reminder during 5 con-
secutive years. Of all women who received a yearly follow-
up letter (1157) and were 5 years in follow-up in the register,
75.0% (868) received at least once a screening test, 60.6%
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Figure 2: Overview of the number of registrations per year in the register over the 7-year period.
4 International Journal of Endocrinology
(701) received at least twice a screening test, 46.6% (539)
received at least three times a screening test, 34.0% (393)
received at least four times a screening test, and 18.3%
(212) of women received yearly a screening test over the
5-year period.
3.3. Survey among Registrants to Evaluate the Perceived
Usefulness of the Reminders. The survey had a response rate
of 26.4% (132), and 70.5% (93) of responders indicated that
the reminders were important to stimulate screening and that
without the reminder, they would not have visited their gen-
eral practitioner for a screening test.
3.4. The Characteristics of Nonresponders Compared to
Responders. Compared to women who responded at least
once to a reminder, women who never responded were more
often <30 years (41.1% versus 33.9%, p < 0 001) and were
more often obese (29.3% versus 20.8%, p = < 0 001).
3.5. The Number of Responders with (Pre)diabetes over Time.
The cumulative risk after 1 year for diabetes and IFG was,
respectively, 3.1% (CI 2.6%–3.7%) and 3.4% (CI 2.9%–
4.1%). After 3 years, the cumulative risk for diabetes and
IFG was, respectively, 5.2% (CI 4.5%–6.1%) and 14.5% (CI
13.1%–16.0%) and after 6 years, the cumulative risk for dia-
betes and IFG increased to, respectively, 7.3% (CI 6.0%–
8.8%) and 27.4% (CI 23.9%–31.0%) (Figure 3).
3.6. Predictors for Prediabetes. In the univariable analyzes,
predictors for diabetes and prediabetes were increasing age,
BMI, and waist circumference, and for diabetes also the fact
that women received a screening test within 3 months after
the delivery (Table 3(a)). In the multivariable analyzes, age
and BMI remained independent predictors for diabetes and
prediabetes and for prediabetes, waist circumference was also
an independent predictor (Table 3(b)).
4. Discussion
Although there is a general consensus that timely detection
and treatment of glucose intolerance after the delivery in
women with GDM is important, postpartum testing rates
in normal routine are often very low [15–19]. In our register,
of all responders, only 58.8% indicated that they received a
screening test within three months after the delivery. This is
a missed opportunity to timely identify and treat high-risk
women for glucose intolerance. Small studies have shown
that the use of reminders sent to patients and/or health pro-
fessionals can increase the postpartum screening uptake [20].
However, very few studies have evaluated the eﬃcacy of
reminders after the ﬁrst year postpartum [20, 21]. We show
now the feasibility and eﬃcacy of a GDM recall register
implemented across 66 centers in Flanders (Belgium). The
response rate was the highest after the ﬁrst year of follow-
up but after 5 years, nearly 62% still responded to the
reminder. The screening rates remained generally stable over
the years and varied from 62.1% to 71.9%. We provide now
the ﬁrst data of the successful use of a GDM recall register
on the long term to stimulate screening postpartum. More-
over, we show now that the register is widely implemented
in a large region as part of normal routine care. However, it
remains challenging to stimulate women to get a yearly
screening test since only 18.3% of women with 5 years of
follow-up in the register reported a screening test every year.
A recent systematic review including 6 studies has shown
that both reminder systems send to patients and/or health
care professionals are successful in increasing postpartum
screening rates with a glucose test performed in 50–71% of
Table 1: An overview of the number of responders and screening tests per year of follow-up.
1 year of
follow-up
2 years of
follow-up
3 years of
follow-up
4 years of
follow-up
5 years of
follow-up
The number of yearly reminders sent 4765 3561 2482 1557 542
Number of responders (%) 3547 (74.4%) 2419 (67.9%) 1542 (62.1%) 877 (60.2%) 335 (61.8%)
Number of responders who received
a screening test (%)
2390 (67.4%) 1502 (62.1%) 1060 (68.7%) 612 (69.8%) 241 (71.9%)
Number with diabetes 104 26 15 3 0
The number of responders is the number of registrants who returned a response sheet. The number of responders who received a screening test is the number of
responders who have indicated that they received a screening test in primary care in the past year. The number with diabetes is based on self-reporting of the test
between 6 and 12 weeks postpartum and based on self-reporting of the screening tests received after 1 year.
Table 2: An overview of the number of responders and screening tests of all registrants who received a yearly reminder during 5 consecutive
years.
Follow-up
year 1
Follow-up
year 2
Follow-up
year 3
Follow-up
year 4
Follow-up
year 5
Number of women who received a follow-up letter 1370 1202 1273 1221 1157
Number of responders (%) 1128 (82.3%) 913 (76.0%) 848 (66.6%) 737 (60.4%) 686 (59.3%)
Number of responders who received a screening test (%) 748 (66.3%) 586 (64.2%) 575 (67.8%) 524 (71.1%) 489 (71.3%)
The number of responders is the number of registrants who returned a response sheet. The number of responders who received a screening test is the number of
responders who have indicated that they received a screening test in primary care in the past year.
5International Journal of Endocrinology
women. However, the evidence is very limited for long-term
eﬀects past the ﬁrst year postpartum [20]. Reminders by tele-
phone seem to be more eﬀective than letters, and with more
frequent reminders, more women will undergo a follow-up
visit over time [20]. The response rate to the reminders was
markedly higher (between 60.2% and 74.4%) in our register
compared to the South Australian GDM recall register where
68.4% of women with GDM registered but only 46.4%
returned the update form [21]. In the South Australian
GDM recall register, women who did not respond to a
reminder letter were not followed up for a response while
our register did not only use annual reminders by letters
and email but if needed, additional email, telephone, or
SMS reminders were used to increase the response rate
[21]. By using extra reminders, the response rates increased
importantly in our register. There is currently only one
RCT in women with GDM that evaluated the use of
reminders to increase screening with an OGTT within 1 year
after the delivery. The study showed that postal reminders
send to patients or physicians alone or send to both patients
and physicians increased screening rates from 14.3% to
51.6%–60.5% [27]. The highest screening rate postpartum
(60.5%) was seen in the combined patient/physician group
[27]. However, when this reminder system was implemented
into routine care, screening rates postpartum only increased
to 28% [28]. Although we have no data on the long-term
screening uptake postpartum before the use of the register
in Belgium, many studies have shown a long-term screening
uptake of max. 20% in normal routine [18, 19]. A survey
among participants has shown that for many women, the
reminders were perceived very useful to stimulate screening.
Our data highlight therefore that our GDM recall register
implemented in routine clinical care is feasible with sustained
high registration and response rates.
Age and BMI of registrants were similar as previously
reported in women with GDM from two large Flemish hos-
pitals, but the register does not have any data on ethnicity or
the socioeconomic status of the participants [29]. Compared
to women who responded at least once to a reminder,
women who never responded to a reminder in our register
were more often <30 years and were more often obese.
Younger women may underestimate their risk to develop
glucose intolerance while women with a higher risk proﬁle
such as obese women are often diﬃcult to engage in screen-
ing programs [30, 31]. It has been shown that the nonatten-
dance rate at the postpartum OGTT is particularly high in
women from an ethnic minority background and women
with an adverse metabolic proﬁle [30, 31]. These women
have often the highest risk to develop glucose intolerance
postpartum, and more eﬀorts are clearly needed to stimulate
these women to attend the postpartum screening tests [31].
Important barriers to postpartum screening are the lack of
patient attendance, most often due to time pressure, clini-
cians’ perception that screening guidelines are inconsistent,
lack of documentation of GDM in the medical ﬁle, and poor
communication between obstetricians and primary care pro-
viders [12–14, 32]. Studies have shown that predictors of
higher screening rates include older age, nulliparity, and
higher income and education. Women who received prena-
tal care, women who needed insulin during pregnancy or
who came to the 6-week postpartum visit, were also more
likely to receive screening [13, 14, 32]. This might explain
why women who received a screening test in early postpar-
tum in our register were more likely to develop diabetes over
time as women who adhere better to early postpartum
screening might also adhere better to follow-up screening.
Prevalence of glucose intolerance after the delivery in
women with GDM varies according to the population
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Figure 3: Cumulative risk of diabetes and prediabetes over time since the delivery (+95% CI). The crossing of the two curves is the result of
data registration: diabetes may have been detected and registered at 3-month postnatal screening, hence the “bump” around 3 months in the
curve for diabetes. Prediabetes was only registered at long-term yearly follow-up with the GP, hence the “bump” around 12 months (and with
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6 International Journal of Endocrinology
studied and how women with GDMwere identiﬁed. We have
previously shown that in a large university center in Flanders,
about 44% of women with GDM diagnosed by a two-step
approach with the Carpenter and Coustan criteria or the
2013 WHO criteria for GDM had glucose intolerance based
on the 75 g OGTT three months after the delivery [30, 31].
On the long term, studies have shown that 16–50% of women
with GDM develop type 2 diabetes [8, 13, 33, 34]. Our data
show now that over a period of 6 years, 27.4% of all
responders developed IFG and 7.3% developed diabetes.
The Flemish guideline for the diagnosis and treatment of
type 2 diabetes recommends a FPG as screening test instead
of an OGTT because this is more feasible to perform in pri-
mary care [35]. The “Sweet Pregnancy” project chose there-
fore a practical approach for follow-up in primary care with
a FPG as screening test. The FPG may be more acceptable
to women because it requires less time, which in turn might
increase the attendance rates at screening tests and increase
the long-term follow-up postpartum. However, many studies
have shown that by only using a FPG, a substantial number
of women can be missed with diabetes or impaired glucose
tolerance [13, 17, 30, 31]. Moreover, a simulation showed
that when annual, biannual, or every 3-year screening strate-
gies were utilized, OGTTs resulted in lower costs per case
detected than FPG or HbA1c [36]. It is therefore very likely
that the currently reported prevalence of glucose intolerance
with the register is an underestimation. The ADA recom-
mends lifelong screening for the development of glucose
intolerance, at least every 3 years. When glucose intolerance
is found, the frequency of screening should be increased to
at least annually [37]. However, the ADAmakes no clear rec-
ommendation as to which test should be used (HbA1c, FPG,
or 2 h 75 g OGTT) since the ADA considers that there is
insuﬃcient evidence to recommend one test over the other
Table 3: Predictors for diabetes and prediabetes.
(a) Results of univariable analyses
Variable Contrast
Diabetes Diabetes
p value
Prediabetes Prediabetes
p value
Hazard ratio (95% CI) Hazard ratio (95% CI)
Contrast Global Contrast Global
Age category (years)
30–40 versus <30 1.40 (0.98 : 2.00) 0.0646 0.0032 1.10 (0.88 : 1.36) 0.4049 <0.0001
>40 versus <30 2.53 (1.48 : 4.33) 0.0007 — 2.08 (1.47 : 2.93) <0.0001 —
>40 versus 30–40 1.81 (1.12 : 2.91) 0.0151 — 1.90 (1.39 : 2.60) <0.0001 —
BMI category (kg/m2)
25–30 versus <25 1.83 (1.28 : 2.61) 0.0009 <0.0001 1.94 (1.54 : 2.44) <0.0001 <0.0001
>30 versus <25 2.33 (1.61 : 3.38) <0.0001 — 2.77 (2.20 : 3.48) <0.0001 —
>30 versus 25–30 1.28 (0.88 : 1.86) 0.2042 — 1.43 (1.13 : 1.81) 0.0032 —
WC category (cm)
80–88 versus <80 0.63 (0.14 : 2.94) 0.5594 0.0462 1.01 (0.68 : 1.50) 0.9515 <0.0001
>88 versus <80 2.47 (0.79 : 7.74) 0.1208 — 2.39 (1.76 : 3.23) <0.0001 —
>88 versus 80–88 3.90 (1.14 : 13.39) 0.0304 — 2.36 (1.70 : 3.26) <0.0001 —
Support GP Yes 1.09 (0.74 : 1.62) — 0.6617 1.23 (0.96 : 1.57) — 0.1076
Received screening
in early postpartum
Yes 3.07 (2.18 : 4.31) — <0.0001 1.06 (0.88 : 1.27) — 0.5363
WC: waist circumference; support GP: general practitioner conﬁrmed active support for the recall register; received screening in early postpartum: between 6
and 12 weeks after the delivery; HR: hazard ratio; CI: conﬁdence interval; p values: global for the variable as a whole; contrast for diﬀerence between 2 categories;
HR > (<)1 means higher (lower) risk for the ﬁrst category.
(b) Results of multivariable model
Variable Contrast
Diabetes Diabetes
p value
Prediabetes Prediabetes
p value
Hazard ratio (95% CI) Hazard ratio (95% CI)
Contrast Global Contrast Global
Age category (years)
30–40 versus <30 2.41 (0.67 : 8.69) 0.1799 0.0195 1.18 (0.89 : 1.58) 0.2506 0.0388
>40 versus <30 6.75 (1.64 : 27.85) 0.0082 — 1.84 (1.15 : 2.93) 0.0108 —
>40 versus 30–40 2.81 (1.06 : 7.41) 0.0373 — 1.55 (1.02 : 2.36) 0.0396 —
BMI category (kg/m2)
25–30 versus <25 6.01 (2.42 : 14.92) 0.0001 <0.0001 1.55 (1.09 : 2.21) 0.0145 0.0001
>30 versus <25 8.19 (2.92 : 23.01) <0.0001 — 2.30 (1.57 : 3.37) <0.0001 —
>30 versus 25–30 1.36 (0.56 : 3.31) 0.4935 — 1.48 (1.08 : 2.03) 0.0152 —
WC category (cm)
80–88 versus <80 0.37 (0.10 : 1.32) 0.1252 0.2203 0.88 (0.59 : 1.32) 0.5414 0.0380
>88 versus <80 0.59 (0.25 : 1.38) 0.2220 — 1.41 (0.95 : 2.11) 0.0906 —
>88 versus 80–88 1.61 (0.43 : 6.06) 0.4822 — 1.61 (1.10 : 2.34) 0.0133 —
WC: waist circumference; HR: hazard ratio; CI: conﬁdence interval; p values: global for the variable as a whole; contrast for diﬀerence between 2 categories;
HR > (<)1 means higher (lower) risk for the ﬁrst category.
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[1]. Studies evaluating the use of HbA1c alone or in combina-
tion with FPG to diagnose glucose intolerance in women
who have had GDM show conﬂicting results with sensitivity
rates of HbA1c and FPG combined ranging from 83.0% to
90.0% [38, 39]. We have no data on HbA1c in our register.
The most important risk factors to develop glucose
intolerance in early postpartum diﬀer according to the pop-
ulations studied [40]. Maternal age, prepregnancy weight,
early GDM diagnosis, pharmaceutical treatment during
pregnancy, and the FPG on the diagnostic OGTT during
pregnancy often emerge as important risk factors for glu-
cose intolerance postpartum [17, 40, 41]. This is in line with
our data showing that women with a higher age, BMI, and
waist circumference had the highest risk for glucose intoler-
ance postpartum.
Strengths of our register are the large number of partici-
pating centers across a large region with a long follow-up.
The recall register is widely implemented, and nonre-
sponders receive systematically a new reminder by email,
telephone, or SMS. Limitations are the limited clinical data
in the register, and the data obtained are self-reported by
the registrants. Self-reporting of screening tests might have
overestimated the screening uptake postpartum due to selec-
tion of the most engaged women [32]. Due to the lack of
uniformity on screening for GDM in Flanders, there are dif-
ferences between centers in how women with GDM were
diagnosed. We could also not evaluate whether the missed
tests are due to lack of order by the doctor or because women
did not visit the doctor. From the group of registrants who
did not respond, we have no information on whether or
not they received a screening test. As we have no data on
women who were not oﬀered registration or did not want
to register, we do not have a control group to compare the
eﬃcacy of reminders with on screening uptake postpartum.
For future research, the database should be extended with
data on the socioeconomic status and the ethnicity of regis-
trants. Linking the register to the general electronic health
record will be an important step to collect and validate more
data on the registrants.
In conclusion, we show now the long-term feasibility and
eﬃcacy of a GDM recall register implemented as part of nor-
mal routine in a large region to stimulate screening postpar-
tum. One-third of women developed prediabetes within 6
years based on the FPG. However, more research is necessary
to better understand how to engage and stimulate high-risk
women to respond.
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